Dergiler / Türk Onkoloji Dergisi / 2017 / Cilt: 32 - Sayı: 1

Role of Circulating Tumor Cells and Cell-Free Tumor Deoxyribonucleic Acid Fragments as Liquid Biopsy Materials in Breast Oncology

Sayfa
35–41
Yayın Tarihi
2022-11-03
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This review is a discussion of current status of utilization of these liquid biopsy materials in breast oncology

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Breast cancer is the most commonly diagnosed type of cancer among females worldwide.
📊
Temel Bulgular & Veri:Though novel biomarkers and new strategies for diagnosis, monitoring course of disease, and treatment of breast cancer have been found, these methods are invasive, costly, labor-intensive, and inadequate to fully gauge treatment response and disease recurrence.
💡
Sonuç & Katkı:This review is a discussion of current status of utilization of these liquid biopsy materials in breast oncology
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Breast cancer is the most commonly diagnosed type of cancer among females worldwide. It is also the leading cause of female cancer-related death in developing countries. Though novel biomarkers and new strategies for diagnosis, monitoring course of disease, and treatment of breast cancer have been found, these methods are invasive, costly, labor-intensive, and inadequate to fully gauge treatment response and disease recurrence. Therefore, novel biomarkers with greater sensitivity and specificity, and which are easy to perform are needed in breast cancer oncology. There is growing interest in the potential use of circulating tumor cells and circulating tumor deoxyribonucleic acid fragments in liquid biopsy as non-invasive biopsy materials for early detection of breast cancer, monitoring disease progression, and understanding reasons for treatment resistance. This review is a discussion of current status of utilization of these liquid biopsy materials in breast oncology

🔖

Bu Makaleye Atıf Yap

AKILLILAR, P. T., YILDIZ, G. (2022). Role of Circulating Tumor Cells and Cell-Free Tumor Deoxyribonucleic Acid Fragments as Liquid Biopsy Materials in Breast Oncology. Türk Onkoloji Dergisi, Cilt: 32 - Sayı: 1, 35–41. https://ajindex.com/articles/639289

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2015;65(2):87-108
  2. Özmen V. Breast cancer in the world and Turkey. J Breast Health 2008;4(2)
  3. Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: A practical perspective. Clin Biochem Rev 2011;32(4):177-95
  4. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: An overview. Cancers 2014;6(3):1769-92
  5. Duffy MJ, Evoy D, McDermott EW. CA 15-3: Uses and limitation as a biomarker for breast cancer. Clin Chim Acta 2010;411(23-24):1869-74
  6. Alix-Panabières C and Pantel K. Circulating tumor cells: Liquid biopsy of cancer. Clin Chem 2013;59(1):110-8
  7. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: Monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013;10(8):472-84
  8. Park Y, Kitahara T, Urita T, Yoshida Y and Kato R. Expected clinical applications of circulating tumor cells in breast cancer. World J Clin Oncol 2011;2:303-310
  9. Asworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Australas Med J 1869;14:146-7. 10.Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga JY, et al. Circulating tumor cells: clinical validity and utility. Int J Clin Oncol 2017; Epub ahead of print. 11.Lee JS, Magbanua MJ, Park JW. Circulating tumor cells in breast cancer: applications in personalized medicine. Breast Cancer Res Treat 2016;160(3):411-424. 12.Bulfoni M, Turetta M, Del Ben F, Di Loreto C, Beltrami AP and Cesselli D. Dissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the Haystack. Int J Mol Sci 2016;17(10)pii: E1775. 13.Banys-Paluchowski M, Krawczyk N and Fehm T. Potential Role of Circulating Tumor Cell Detection and Monitoring in Breast Cancer: A Review of Current Evidence. Front Oncol 2016;6:255. 14.Pantel K, Alix-Panabiéres C and Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009; 6:339e351. 15.Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 2014; 106(5):pii:dju066. 16.Janni WJ, Rack B, Terstappen LW, Pierga JY, Taran FA, Fehm T, et al. Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Cli